SCHEDULE 13G/A: Morgan Stanley Reduces Stake in Marinus Pharmaceuticals, Ceases to Be Major Shareholder

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported ceasing to be beneficial owners of more than five percent of Marinus Pharmaceuticals, Inc.'s common stock as of February 28, 2025.

Summary

• Morgan Stanley and Morgan Stanley & Co. LLC filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Marinus Pharmaceuticals, Inc.
• As of February 28, 2025, both Morgan Stanley and Morgan Stanley & Co. LLC ceased to be beneficial owners of more than five percent of Marinus Pharmaceuticals, Inc.'s common stock.
• Their aggregate beneficial ownership of Marinus Pharmaceuticals, Inc. common stock is now reported as 0.0%.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing reporting a change in beneficial ownership, specifically a reduction below a reporting threshold. It contains no information about the issuer's performance, strategy, or financial health, making its direct sentiment impact neutral from the issuer's perspective, though a large investor reducing stake could be interpreted differently by the market.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the reduction in stake by a major institutional investor, which could influence market perception regarding institutional confidence or portfolio rebalancing.

Key Dates

Keywords

Marinus Pharmaceuticals, Morgan Stanley, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Change